Pseudouridine from BOC Sciences is Accelerating the Production of COVID-19 mRNA Vaccines

BOC Sciences has been providing high-quality pseudouridine and its derivatives, especially N1-methylpseudouridine, for the production of COVID-19 mRNA vaccines.

New York, USA – July 30, 2021 – The new coronavirus SARS-CoV-2 that caused the COVID-19 pandemic has inspired one of the most effective vaccine development activities in human history. And the mRNA vaccine is a new type of vaccine first approved by the FDA.

As a leading supplier of chemical and pharmaceutical raw materials, BOC Sciences has been providing high-quality pseudouridine and its derivatives, especially N1-methylpseudouridine (m1Ψ), for the production of COVID-19 mRNA vaccines. And its continuously optimized and upgraded GMP manufacturing platform is becoming a strong guarantee for the supply of COVID-19 mRNA vaccine raw materials. At present, BOC Sciences’s annual output of pseudouridine has exceeded 500 kg, making it the largest producer of pseudouridine in the world.

N1-Methylpseudouridine substitution enhances the performance of synthetic COVID-19 mRNA

The key point in the structural design of the COVID-19 mRNA vaccine is to use the modified nucleobase N1-methylpseudouridine (m1Ψ) to improve its effectiveness. N1-methylpseudouridine is a modification naturally found in 18S rRNA. As a precursor of N1-methyl-N3-(3-amino-3-carboxypropyl) pseudouridine (m1acp3Ψ), when N1-methyl pseudouridine is incorporated alone or in combination with m5C, it will drastically improve the translational capacity of mRNA. This means that in the synthesis of modified mRNA, N1-methylpseudouridine can be used as a substitute for UTP, and compared with other modified bases, m1Ψ substitution induces higher mRNA protein expression. Moreover, it was also found that N1-methylpseudouridine can reduce the activation of TLR3 and there reduce the immunogenicity of synthetic mRNA.

About mRNA Vaccines

The COVID-19 mRNA vaccine, BNT162b2, is a highly purified single-stranded, 5′-end-capped messenger RNA (mRNA), produced from the corresponding DNA template by in vitro transcription, encoding the SARS-CoV-2 mutant virus spike (S) protein. The vaccine is formulated into RNA lipid nanoparticles (LNPs) containing N1-methylpseudouridine instead of uridine-modified nucleoside mRNA. After injection, LNPs are taken up by cells and RNA is released into the cytoplasm. In the cytosol, RNA is translated into encoded viral proteins (viral spike protein antigens), which can induce adaptive immune responses through neutralizing antibodies. In addition, as the expressed spike (S) protein is degraded in the cell, the peptides produced can be displayed on the cell surface to trigger a specific T cell-mediated immune response and have activity against viruses and infected cells.

About BOC Sciences

BOC Sciences has well-known experts in multiple disciplines such as drug discovery, chemistry, and life sciences, and is a reliable supplier that provides a comprehensive collection of chemicals for scientists and researchers in academia and industry. It has won the reputation and precious trust of global customers in the supply of chemicals such as nucleosides/nucleotides, pseudouridines. For more information on pseudouridine and/or N1-methylpseudouridine, please visit the website of BOC Sciences:

Media Contact
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1-631-485-4226
Country: United States